Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Roth Capital upgrades Kodiak Sciences to Buy on recent selloff » 09:36
05/11/21
05/11
09:36
05/11/21
09:36
KOD

Kodiak Sciences

$87.72 /

-13.98 (-13.75%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah upgraded Kodiak Sciences to Buy from Neutral with a price target of $149, down from $155. Most notable in yesterday's earnings update was the announcement that Kodiak will now be initiating an additional Phase 3 wet age-related macular degeneration study to support four-week interval dosing of its lead drug, KSI-301, Jallah tells investors in a research note. The analyst finds the change necessary given Beovu's label challenges, and does not expect this to significantly shift the Biologics License Application timeline. With recent setbacks facing competitors, KSI-301's commercial outlook "remains strong," says Jallah. She believes the recent pullback in shares of Kodiak Sciences presents a buying opportunity.

ShowHide Related Items >><<
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

05/11/21 Roth Capital
Kodiak Sciences upgraded to Buy from Neutral at Roth Capital
05/11/21 BMO Capital
Kodiak Sciences price target lowered to $104 from $138 at BMO Capital
05/11/21 Barclays
Kodiak Sciences price target lowered to $86 from $90 at Barclays
05/04/21 Truist
Kodiak Sciences price target raised to $147 from $89 at Truist
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

  • 18
    Nov
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

Upgrade
Kodiak Sciences upgraded to Buy from Neutral at Roth Capital » 09:32
05/11/21
05/11
09:32
05/11/21
09:32
KOD

Kodiak Sciences

$87.72 /

-13.98 (-13.75%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah upgraded Kodiak Sciences to Buy from Neutral with a $149 price target.

ShowHide Related Items >><<
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

05/11/21 BMO Capital
Kodiak Sciences price target lowered to $104 from $138 at BMO Capital
05/11/21 Barclays
Kodiak Sciences price target lowered to $86 from $90 at Barclays
05/04/21 Truist
Kodiak Sciences price target raised to $147 from $89 at Truist
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

  • 18
    Nov
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

Recommendations
Kodiak Sciences price target lowered to $104 from $138 at BMO Capital » 06:52
05/11/21
05/11
06:52
05/11/21
06:52
KOD

Kodiak Sciences

$87.72 /

-13.98 (-13.75%)

BMO Capital analyst…

BMO Capital analyst Matthew Luchini lowered the firm's price target on Kodiak Sciences to $104 from $138 and keeps a Market Perform rating on the shares. The company's Q1 earnings missed expectations and while the new monthly phase 3 wAMD trial should help with labeling, it also adds incremental execution risk that comes with manufacturing site construction delays from COVID-19 vaccine competition, the analyst tells investors in a research note. Luchini is updating his model with assumption of higher spending, BLA launch timing, and a 0.5% higher discount rate on greater overall program risk for Kodiak shares.

ShowHide Related Items >><<
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

05/11/21 Barclays
Kodiak Sciences price target lowered to $86 from $90 at Barclays
05/04/21 Truist
Kodiak Sciences price target raised to $147 from $89 at Truist
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/02/21 BMO Capital
Kodiak Sciences price target lowered to $138 from $148 at BMO Capital
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

  • 18
    Nov
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

Recommendations
Kodiak Sciences price target lowered to $86 from $90 at Barclays » 06:52
05/11/21
05/11
06:52
05/11/21
06:52
KOD

Kodiak Sciences

$87.72 /

-13.98 (-13.75%)

Barclays analyst Gena…

Barclays analyst Gena Wang lowered the firm's price target on Kodiak Sciences to $86 from $90 and keeps an Underweight rating on the shares post the Q1 results.

ShowHide Related Items >><<
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

05/04/21 Truist
Kodiak Sciences price target raised to $147 from $89 at Truist
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/02/21 BMO Capital
Kodiak Sciences price target lowered to $138 from $148 at BMO Capital
03/01/21 Roth Capital
Kodiak Sciences well positioned to 'execute on all fronts,' says Roth Capital
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

  • 18
    Nov
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

Monday
Syndicate
Kodiak Sciences files to sell 14.03M shares of common stock for holders  17:33
05/10/21
05/10
17:33
05/10/21
17:33
KOD

Kodiak Sciences

$87.72 /

-13.98 (-13.75%)

 
ShowHide Related Items >><<
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

05/04/21 Truist
Kodiak Sciences price target raised to $147 from $89 at Truist
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/02/21 BMO Capital
Kodiak Sciences price target lowered to $138 from $148 at BMO Capital
03/01/21 Roth Capital
Kodiak Sciences well positioned to 'execute on all fronts,' says Roth Capital
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

  • 18
    Nov
KOD Kodiak Sciences
$87.72 /

-13.98 (-13.75%)

Earnings
Kodiak Sciences reports Q1 EPS (98c), consensus (97c) » 05:43
05/10/21
05/10
05:43
05/10/21
05:43
KOD

Kodiak Sciences

$101.41 /

+0.18 (+0.18%)

Kodiak ended Q1 with…

Kodiak ended Q1 with $929M of cash, cash equivalents and marketable securities. "Developing and launching a novel anti-VEGF medicine with extended durability is the central principle of our KSI-301 development program, and in the last quarter we have continued to make substantial progress in the recruitment of our pivotal studies evaluating long-interval dosing of KSI-301," said Jason Ehrlich, CMO of Kodiak. "Our wet AMD pivotal study, DAZZLE, is fully enrolled, and our RVO and DME pivotal studies are all recruiting globally. Each is evaluating KSI-301's potential for best-in-class dosing regimens. Towards our goal of having KSI-301 be the anti-VEGF medicine of choice for all eligible patients, and through our continued engagement with the retina community, we have also learned that physicians and retina practices would like to see our labeling for KSI-301 include the option for more frequent dosing. This reduces barriers to reimbursement that have impeded the commercial uptake of other anti-VEGF medications in the past. A study of more intensive dosing also allows us to explore the potential for improved treatment outcomes in certain patients. Thus, we are launching the DAYLIGHT study which will evaluate monthly dosing of KSI-301 in patients with wet AMD. We believe that pursuing a very broad product label will provide physicians with the flexibility, agency, and reimbursement confidence required to individualize treatment for their patients. Based on our discussions with regulators, we also believe the DAYLIGHT study will provide the safety database needed to support monthly labeling not only in wet AMD but in the DME and RVO indications in the US as well. We expect recruitment in DAYLIGHT will begin in the summer of 2021, and we plan to include data from this fifth pivotal study of KSI-301 in our initial BLA submission."

ShowHide Related Items >><<
KOD Kodiak Sciences
$101.41 /

+0.18 (+0.18%)

KOD Kodiak Sciences
$101.41 /

+0.18 (+0.18%)

05/04/21 Truist
Kodiak Sciences price target raised to $147 from $89 at Truist
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/02/21 BMO Capital
Kodiak Sciences price target lowered to $138 from $148 at BMO Capital
03/01/21 Roth Capital
Kodiak Sciences well positioned to 'execute on all fronts,' says Roth Capital
KOD Kodiak Sciences
$101.41 /

+0.18 (+0.18%)

  • 18
    Nov
KOD Kodiak Sciences
$101.41 /

+0.18 (+0.18%)

Over a week ago
Conference/Events
Truist to hold a virtual summit » 09:02
05/04/21
05/04
09:02
05/04/21
09:02
INFI

Infinity Pharmaceuticals

/

+

, XAIR

Beyond Air

/

+

, KOD

Kodiak Sciences

/

+

, ARCT

Arcturus Therapeutics

/

+

, SIBN

SI-Bone

/

+

, EXEL

Exelixis

/

+

, AFIB

Acutus Medical

/

+

, APTX

Aptinyx

/

+

, CNCE

Concert Pharmaceuticals

/

+

, EBS

Emergent BioSolutions

/

+

, FRLN

Freeline

/

+

, LMAT

LeMaitre

/

+

, LTRN

Lantern Pharma

/

+

, NMTR

9 Meters Biopharma

/

+

, STTK

Shattuck Labs

/

+

7th Annual Securities…

7th Annual Securities Life Virtual Summit will be held on May 4-5.

ShowHide Related Items >><<
XAIR Beyond Air
/

+

STTK Shattuck Labs
/

+

SIBN SI-Bone
/

+

NMTR 9 Meters Biopharma
/

+

LTRN Lantern Pharma
/

+

KOD Kodiak Sciences
/

+

INFI Infinity Pharmaceuticals
/

+

FRLN Freeline
/

+

EXEL Exelixis
/

+

EBS Emergent BioSolutions
/

+

CNCE Concert Pharmaceuticals
/

+

ARCT Arcturus Therapeutics
/

+

APTX Aptinyx
/

+

AFIB Acutus Medical
/

+

INFI Infinity Pharmaceuticals
/

+

03/23/21 B. Riley
Infinity Pharmaceuticals price target lowered to $7 from $8 at B. Riley
03/18/21 Truist
Infinity Pharmaceuticals initiated with a Buy at Truist
03/18/21 Truist
Infinity Pharmaceuticals initiated with a Buy at Truist
03/17/21 JonesTrading
Infinity Pharmaceuticals has 'catalyst heavy' 2021, says JonesTrading
XAIR Beyond Air
/

+

04/28/21
Fly Intel: Top five analyst initiations
04/28/21 Truist
Beyond Air initiated with a Buy at Truist
04/28/21 Truist
Beyond Air initiated with a Buy at Truist
KOD Kodiak Sciences
/

+

05/04/21 Truist
Kodiak Sciences price target raised to $147 from $89 at Truist
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/02/21 BMO Capital
Kodiak Sciences price target lowered to $138 from $148 at BMO Capital
03/01/21 Roth Capital
Kodiak Sciences well positioned to 'execute on all fronts,' says Roth Capital
ARCT Arcturus Therapeutics
/

+

04/26/21 B. Riley
B. Riley reiterates Buy on Novavax, Sell on Arcturus amid vaccine developments
03/08/21 B. Riley
Arcturus Therapeutics price target lowered to $35 from $45 at B. Riley
03/02/21 Roth Capital
Arcturus Therapeutics price target lowered to $45 from $77 at Roth Capital
02/17/21 B. Riley
B. Riley downgrades Arcturus to Sell, removes COVID-19 vaccine from model
SIBN SI-Bone
/

+

05/04/21 Truist
SI-Bone price target raised to $43 from $35 at Truist
05/04/21 Needham
SI-Bone price target raised to $42 from $34 at Needham
01/08/21 JMP Securities
SI-Bone price target raised to $35 from $27 at JMP Securities
12/17/20 Canaccord
SI-Bone price target raised to $34 from $30 at Canaccord
EXEL Exelixis
/

+

03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
03/11/21 Wolfe Research
Exelixis initiated with an Outperform at Wolfe Research
02/15/21 Piper Sandler
Exelixis price target raised to $36 from $33 at Piper Sandler
AFIB Acutus Medical
/

+

03/19/21 Canaccord
Acutus Medical price target lowered to $16 from $30 at Canaccord
03/19/21 William Blair
Acutus Medical downgraded to Market Perform from Outperform at William Blair
03/19/21 JPMorgan
Acutus Medical downgraded to Neutral with $19 target at JPMorgan
03/19/21 JPMorgan
Acutus Medical downgraded to Neutral from Overweight at JPMorgan
APTX Aptinyx
/

+

01/29/21 JPMorgan
Aptinyx downgraded to Underweight from Neutral at JPMorgan
12/21/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Aptinyx after competitor fails in PTSD
11/19/20 H.C. Wainwright
Aptinyx price target raised to $8 from $7 at H.C. Wainwright
11/12/20 Piper Sandler
Aptinyx pipeline catalysts on track, says Piper Sandler
CNCE Concert Pharmaceuticals
/

+

02/02/21 Truist
Concert Pharmaceuticals price target lowered to $22 from $30 at Truist
02/02/21 Mizuho
Concert shares oversold on schizophrenia failure, says Mizuho
02/02/21 H.C. Wainwright
Concert Pharmaceuticals price target lowered to $17 from $25 at H.C. Wainwright
02/01/21 JMP Securities
JMP cuts Concert Pharmaceuticals target but still sees 'compelling upside'
EBS Emergent BioSolutions
/

+

04/30/21 Chardan
Emergent BioSolutions price target lowered to $92 from $112 at Chardan
04/30/21 Benchmark
Emergent BioSolutions price target lowered to $120 from $150 at Benchmark
04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
FRLN Freeline
/

+

03/22/21 Mizuho
Freeline initiated with a Buy at Mizuho
03/01/21 Stifel
Freeline initiated with a Buy at Stifel
11/25/20 Redburn
Freeline initiated with a Neutral at Redburn
09/01/20 Evercore ISI
Freeline initiated with an Outperform at Evercore ISI
LMAT LeMaitre
/

+

04/30/21 Lake Street
LeMaitre price target raised to $65 from $55 at Lake Street
04/30/21 Barrington
LeMaitre price target raised to $59 from $49 at Barrington
02/26/21 Barrington
LeMaitre price target raised to $49 from $47 at Barrington
02/12/21
Fly Intel: Top five analyst initiations
LTRN Lantern Pharma
/

+

08/10/20 ThinkEquity
Lantern Pharma initiated with a Buy at ThinkEquity
07/28/20 Colliers
Drug 'rescuer' Lantern Pharma started at Buy at Colliers
07/28/20 Colliers
Lantern Pharma initiated with a Buy at Colliers
NMTR 9 Meters Biopharma
/

+

03/25/21 Brookline
9 Meters Biopharma assumed with a Buy at Brookline
01/28/21 Oppenheimer
9 Meters Biopharma initiated with an Outperform at Oppenheimer
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Maxim
9 Meters Biopharma initiated with a Buy at Maxim
STTK Shattuck Labs
/

+

04/14/21 Berenberg
Shattuck Labs initiated with a Buy at Berenberg
01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
01/11/21 Evercore ISI
Shattuck Labs initiated with an Outperform at Evercore ISI
11/03/20 Needham
Shattuck Labs initiated with a Buy at Needham
XAIR Beyond Air
/

+

STTK Shattuck Labs
/

+

SIBN SI-Bone
/

+

NMTR 9 Meters Biopharma
/

+

LTRN Lantern Pharma
/

+

KOD Kodiak Sciences
/

+

INFI Infinity Pharmaceuticals
/

+

EXEL Exelixis
/

+

EBS Emergent BioSolutions
/

+

CNCE Concert Pharmaceuticals
/

+

ARCT Arcturus Therapeutics
/

+

APTX Aptinyx
/

+

AFIB Acutus Medical
/

+

  • 31
    Mar
  • 12
    Feb
  • 15
    Jan
  • 11
    Dec
  • 08
    Dec
  • 18
    Nov
  • 22
    Oct
  • 15
    Oct
  • 09
    Oct
  • 06
    Aug
  • 07
    Aug
  • 29
    Jul
  • 11
    Jun
EBS Emergent BioSolutions
/

+

CNCE Concert Pharmaceuticals
/

+

NMTR 9 Meters Biopharma
/

+

KOD Kodiak Sciences
/

+

EXEL Exelixis
/

+

EBS Emergent BioSolutions
/

+

CNCE Concert Pharmaceuticals
/

+

ARCT Arcturus Therapeutics
/

+

AFIB Acutus Medical
/

+

NMTR 9 Meters Biopharma
/

+

LTRN Lantern Pharma
/

+

INFI Infinity Pharmaceuticals
/

+

ARCT Arcturus Therapeutics
/

+

APTX Aptinyx
/

+

AFIB Acutus Medical
/

+

Recommendations
Kodiak Sciences price target raised to $147 from $89 at Truist » 08:18
05/04/21
05/04
08:18
05/04/21
08:18
KOD

Kodiak Sciences

/

+

Truist analyst Robyn…

Truist analyst Robyn Karnauskas raised the firm's price target on Kodiak Sciences to $147 from $89 and keeps a Buy rating on the shares. The analyst says that her research into potential market share for KSI-301 suggests that some practices will want to use KSI-301 and biosimilars and have also done their own cost-benefit analysis of using a less frequently dosed drug that could still be profitable. Karnauskas adds that she has updated her model, with peak market share going up to 20% from 15% across wAMD, DME and RVO.

ShowHide Related Items >><<
KOD Kodiak Sciences
/

+

KOD Kodiak Sciences
/

+

03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/02/21 BMO Capital
Kodiak Sciences price target lowered to $138 from $148 at BMO Capital
03/01/21 Roth Capital
Kodiak Sciences well positioned to 'execute on all fronts,' says Roth Capital
03/01/21 Barclays
Kodiak Sciences downgraded to Underweight from Equal Weight at Barclays
KOD Kodiak Sciences
/

+

  • 18
    Nov
KOD Kodiak Sciences
/

+

Over a month ago
Hot Stocks
Kronos Bio appoints Taiyin Yang to board of directors » 08:07
03/26/21
03/26
08:07
03/26/21
08:07
KRON

Kronos Bio

$28.45 /

-0.13 (-0.45%)

, GILD

Gilead

$64.00 /

-0.33 (-0.51%)

, KOD

Kodiak Sciences

$119.42 /

+4.24 (+3.68%)

Kronos Bio (KRON)…

Kronos Bio (KRON) announced the appointment of Taiyin Yang, Ph.D., to the company's board of directors. Yang has more than four decades of experience in developing and manufacturing medicines in a variety of therapeutic categories. Additionally, Jakob Loven has notified the company that he will not stand for re-election at the company's 2021 Annual Meeting of Stockholders. Yang currently serves as the executive vice president of Pharmaceutical Development and Manufacturing at Gilead Sciences (GILD), with responsibility for all the company's investigational compounds and marketed products. In addition to Kronos Bio, Yang is currently a member of the board of directors of Kodiak Sciences (KOD).

ShowHide Related Items >><<
KRON Kronos Bio
$28.45 /

-0.13 (-0.45%)

KOD Kodiak Sciences
$119.42 /

+4.24 (+3.68%)

GILD Gilead
$64.00 /

-0.33 (-0.51%)

KRON Kronos Bio
$28.45 /

-0.13 (-0.45%)

11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Jefferies
Kronos Bio initiated with a Buy at Jefferies
11/03/20 Piper Sandler
Kronos Bio initiated with an Overweight at Piper Sandler
11/03/20 Goldman Sachs
Kronos Bio initiated with a Buy at Goldman Sachs
GILD Gilead
$64.00 /

-0.33 (-0.51%)

03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
03/15/21 Piper Sandler
Gilead pact with Merck can bring HIV sustainability, says Piper Sandler
02/12/21 Morgan Stanley
Amgen court decision may have readthrough for Gilead, says Morgan Stanley
02/11/21 Maxim
Galapagos downgraded to Hold at Maxim after discontinued Phase 3 ISABELA trials
KOD Kodiak Sciences
$119.42 /

+4.24 (+3.68%)

03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/02/21 BMO Capital
Kodiak Sciences price target lowered to $138 from $148 at BMO Capital
03/01/21 Roth Capital
Kodiak Sciences well positioned to 'execute on all fronts,' says Roth Capital
03/01/21 Barclays
Kodiak Sciences downgraded to Underweight from Equal Weight at Barclays
KRON Kronos Bio
$28.45 /

-0.13 (-0.45%)

KOD Kodiak Sciences
$119.42 /

+4.24 (+3.68%)

GILD Gilead
$64.00 /

-0.33 (-0.51%)

  • 18
    Nov
  • 09
    Oct
GILD Gilead
$64.00 /

-0.33 (-0.51%)

KRON Kronos Bio
$28.45 /

-0.13 (-0.45%)

KOD Kodiak Sciences
$119.42 /

+4.24 (+3.68%)

GILD Gilead
$64.00 /

-0.33 (-0.51%)

KRON Kronos Bio
$28.45 /

-0.13 (-0.45%)

GILD Gilead
$64.00 /

-0.33 (-0.51%)

Initiation
Kodiak Sciences initiated with an Outperform at Evercore ISI » 17:25
03/11/21
03/11
17:25
03/11/21
17:25
KOD

Kodiak Sciences

$131.87 /

+4.775 (+3.76%)

, REGN

Regeneron

$469.92 /

+1.73 (+0.37%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Evercore ISI analyst Umer…

Evercore ISI analyst Umer Raffat initiated coverage of Kodiak Sciences (KOD) with an Outperform rating. The analyst sees the company's construct as "quite interesting" ahead of a "huge" binary event in wet AMD later this year / in early 2022. Kodiak has a very real shot at showing efficacy differentiation vs. Roche's (RHHBY) faricimab and Regeneron's (REGN) Eylea, Raffat tells investors in a research note.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$469.92 /

+1.73 (+0.37%)

KOD Kodiak Sciences
$131.87 /

+4.775 (+3.76%)

KOD Kodiak Sciences
$131.87 /

+4.775 (+3.76%)

03/02/21 BMO Capital
Kodiak Sciences price target lowered to $138 from $148 at BMO Capital
03/01/21 Roth Capital
Kodiak Sciences well positioned to 'execute on all fronts,' says Roth Capital
03/01/21 Barclays
Kodiak Sciences downgraded to Underweight from Equal Weight at Barclays
02/17/21 Roth Capital
Kodiak Sciences downgraded to Neutral from Buy at Roth Capital
REGN Regeneron
$469.92 /

+1.73 (+0.37%)

03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
02/23/21 Credit Suisse
Regeneron price target raised to $760 from $753 at Credit Suisse
02/16/21 Cantor Fitzgerald
Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald
02/08/21 SVB Leerink
Regeneron price target raised to $640 from $623 at SVB Leerink
RHHBY Roche
$0.00 /

+ (+0.00%)

03/09/21 Citi
Roche price target lowered to CHF 360 from CHF 385 at Citi
03/05/21 Erste Group
Roche downgraded to Hold from Buy at Erste Group
03/03/21 Goldman Sachs
Adaptive Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
02/25/21 Berenberg
Roche price target lowered to CHF 320 from CHF 325 at Berenberg
RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$469.92 /

+1.73 (+0.37%)

KOD Kodiak Sciences
$131.87 /

+4.775 (+3.76%)

  • 18
    Nov
  • 27
    May
RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$469.92 /

+1.73 (+0.37%)

RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$469.92 /

+1.73 (+0.37%)

KOD Kodiak Sciences
$131.87 /

+4.775 (+3.76%)

REGN Regeneron
$469.92 /

+1.73 (+0.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.